Post Covid Symptoms and Investigational Treatment of Covid-19

Mounika Kommuri

doi:10.37022/jcscr.v2i1.597

Kommuri Mounika Priyadarshini Institute of Pharmaceutical Education and Research, 5th mile, Pulladigunta-522017, Guntur, Andhra Pradesh. India.

DOI https://doi.org/10.37022/jcscr.v2i1.597

Abstract

10% to 15% of SARS-CoV-2 infections are thought to exhibit post-COVID-19 symptoms. Common indications and symptoms include dyspnea, exhaustion, elevated heart rate, memory loss, cognitive impairment even months after infection, arthralgia, cognitive abnormalities, and a reduction in life quality. Underlying mental or respiratory conditions, as well as feminine sex, may be risk factors. The cornerstone of treatment is still supportive therapies to move symptoms. The goal of the COVID-19 Scientific Committee of the College of Physicians of Madrid was to provide an early look at these novel medications, immunotherapy advancements, and lessons learned from immune response modulators that have been tested and found to be successful in combating the virus in order to better understand the current state of affairs. In an effort to find a COVID-19 medication that works, it was discovered that the World Health Organization launched a cooperative international clinical trial. Four repurchased medications were evaluated for a clinical trial against COVID-19: remdesivir, lopinavir/ritonavir combo, lopinavir/ritonavir with beta-1a, chloroquine, and hydroxychloroquine. These decisions were based on demonstrated in vitro and in vivo activity against several strains of corona viruses.Keywords: protein loosing enteropathy,rickets,primary intestinal lymphangiectasia, non pitting edema,MCT diet.

Keywords: Covid-19, SARS-CoV-2, Infection, Virus

References

1. Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, Cook JR, Nordvig AS, Shalev D, Sehrawat TS, Ahluwalia N. Post-acute COVID-19 syndrome. Nature medicine. 2021 Apr;27(4):601-15.
https://pubmed.ncbi.nlm.nih.gov/33753937/
2. Wissel BD, Van Camp PJ, Kouril M, Weis C, Glauser TA, White PS, Kohane IS, Dexheimer JW. An interactive online dashboard for tracking COVID-19 in US counties, cities, and states in real time. Journal of the American Medical Informatics Association. 2020 Jul;27(7):1121-5. https://data.who.int/dashboards/covid19/cases?n=c
3. Amulya A, Sirisha V, Rao CB, Chennam JV. CURRENT TRENDS ON ROLE OF NANO PARTICLES ON PULMONARY DISEASES. International Journal of Research in Pharmacy and Chemistry. 2012;2(3):685-703.
4. Sivan M, Taylor S. NICE guideline on long covid. bmj. 2020 Dec 23;371. https://pubmed.ncbi.nlm.nih.gov/33361141/
5. Vehar S, Boushra M, Ntiamoah P, Biehl M. Update to post-acute sequelae of SARS-CoV-2 infection: caring for the'long-haulers'. Cleveland Clinic journal of medicine. 2021 Oct 8. https:// www. researchgate.net/publication/351328051_Post-acute_sequelae_of_SARS-CoV-2_infection_Caring_for_the_'long-haulers'
6. Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JV. A clinical case definition of post-COVID-19 condition by a Delphi consensus. The Lancet infectious diseases. 2022 Apr 1;22(4):e102-7. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8691845/
7. Gindi S, Hawisa NT, Baburao C, Khagga M. Role of Ficus bengalensis leaves as a hepatoprotective on rifampicin induced hepatic damage in albino rats. Research Journal of Pharmacology and Pharmacodynamics. 2010;2(6):378-9.
8. Dey B, Hwisa NT, Khalf AM, Mitra A, Katakam P, Rao CB. Pharmaco-epidemiological Studies on Self Medication and Drug Utilization Pattern in Chronic Diseases via Prescription Auditing. International Journal of Scientific Research in Knowledge. 2013 Nov 1;1(11):464. (PDF) Pharmaco-epidemiological Studies on Self Medication and Drug Utilization Pattern in Chronic Diseases via Prescription Auditing (researchgate.net)
9. Taquet M, Dercon Q, Luciano S, Geddes JR, Husain M, Harrison PJ. Incidence, co-occurrence, and evolution of long-COVID features: A 6-month retrospective cohort study of 273,618 survivors of COVID-19. PLoS medicine. 2021 Sep 28;18(9):e1003773. https://pubmed.ncbi.nlm.nih.gov/34582441/
10. Augustin M, Schommers P, Stecher M, Dewald F, Gieselmann L, Gruell H, Horn C, Vanshylla K, Di Cristanziano V, Osebold L, Roventa M. Post-COVID syndrome in non-hospitalised patients with COVID-19: a longitudinal prospective cohort study. The Lancet Regional Health–Europe. 2021 Jul 1;6. https://www.thelancet.com/journals/lanepe/article/PIIS2666-7762(21)00099-5/fulltext
11. Larsen NW, Stiles LE, Miglis MG. Preparing for the long-haul: autonomic complications of COVID-19. Autonomic Neuroscience. 2021 Nov 1;235:102841. https://pubmed.ncbi.nlm.nih.gov/34265539/
12. Raman B, Bluemke DA, Lüscher TF, Neubauer S. Long COVID: post-acute sequelae of COVID-19 with a cardiovascular focus. European heart journal. 2022 Mar 14;43(11):1157-72. https://pubmed.ncbi.nlm.nih.gov/35176758/
13. Moulson N, Petek BJ, Drezner JA, Harmon KG, Kliethermes SA, Patel MR, Baggish AL. SARS-CoV-2 cardiac involvement in young competitive athletes. Circulation. 2021 Jul 27;144(4):256-66. https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.121.054824
14. Graham EL, Clark JR, Orban ZS, Lim PH, Szymanski AL, Taylor C, DiBiase RM, Jia DT, Balabanov R, Ho SU, Batra A. Persistent neurologic symptoms and cognitive dysfunction in non‐hospitalized Covid‐19 “long haulers”. Annals of clinical and translational neurology. 2021 May;8(5):1073-85. https://onlinelibrary.wiley.com/doi/10.1002/acn3.51350
15. Ravella S, Angel M, Subramanian H, Thangavel N, Namballa M, Lokesh D, Mishra AK, Nagaraju GV. Navigating the Future of Cancer Diagnosis: A Comprehensive Review of Novel Approaches for Community-Based Treatment. future.;1:6.
16. McMahon DE, Gallman AE, Hruza GJ, Rosenbach M, Lipoff JB, Desai SR, French LE, Lim H, Cyster JG, Fox LP, Fassett MS. Long COVID in the skin: a registry analysis of COVID-19 dermatological duration. The Lancet Infectious Diseases. 2021 Mar 1;21(3):313-4. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7836995/
17. Sudre CH, Murray B, Varsavsky T, Graham MS, Penfold RS, Bowyer RC, Pujol JC, Klaser K, Antonelli M, Canas LS, Molteni E. Attributes and predictors of long COVID. Nature medicine. 2021 Apr;27(4):626-31.
18. Jacobs LG, Gourna Paleoudis E, Lesky-Di Bari D, Nyirenda T, Friedman T, Gupta A, Rasouli L, Zetkulic M, Balani B, Ogedegbe C, Bawa H. Persistence of symptoms and quality of life at 35 days after hospitalization for COVID-19 infection. PloS one. 2020 Dec 11;15(12):e0243882.
19. Chopra V, Flanders SA, O’Malley M, Malani AN, Prescott HC. Sixty-day outcomes among patients hospitalized with COVID-19. Annals